drugset / Trial / NCT02977507

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

NCT02977507

Completed 18 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.

Timeline

Start
2016-12-13
Primary completion
2017-10-09
Completion
2017-10-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydroquinone Small molecule 4 % Topical